Effect of triftazin (trifluoperazine) on the symptoms of autism spectrum disorders in rats with fetal valproatate syndrome
Abstract
The effect of triftazin (trifluoperazine) on social interaction abnormalities as a main feature of autism spectrum disorders, exploratory behavior and learning capacity was studied in rats with fetal valproatate syndrome. It was shown that triftazin at a dose of 0,35 mg/kg does not affect the deficit of social interaction, spatial learning or memory but improves exploratory activity by decreasing anxiety in rats with fetal valproate syndrome.
About the Authors
I. G. Kapitsa
ФГБНУ «НИИ фармакологии имени В.В. Закусова»
Russian Federation
Russian Federation
E. A. Ivanova
ФГБНУ «НИИ фармакологии имени В.В. Закусова»
Russian Federation
Russian Federation
T. A. Voronina
ФГБНУ «НИИ фармакологии имени В.В. Закусова»
Russian Federation
Russian Federation
G. V. Protsun
ФГБНУ «НИИ фармакологии имени В.В. Закусова»
Russian Federation
Russian Federation
References
1. IACAPAP Textbook of Child and Adolescent Mental Health. Autism spectrumdisorder 2015; 2: 1-38.
2. Wallace S., Fein D., Rosanoff M., et al. A global public health strategy for autism spectrum disorders. Autism Res. 2012; 5 (3): 211-217.
3. Психиатрия детского и подросткового возраста под ред. Гилл-берга К., Хеллгрена Л., рус. изд. / под общ. ред. акад. РАМН Сидорова П.И. М.: ГЭОТАР-МЕД, 2004; 544.
4. Симашкова Н.В. Эффективная фармакотерапия и реабилитация больных с расстройствами аутистического спектра. Неврология и психиатрия 2011; 3: 14-22.
5. Шапошникова А.Ф. Медикаментозное лечение при детском аутизме. Аутизм и нарушение развития. 2008; 3: 43 -48.
6. Doyle C.A., McDougle C.J. Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan. Dialogues Clin Neurosci. 2012; 14: 263-279.
7. Венгеровский А.И. Лекции по фармакологии для врачей и провизоров. М.: Физматлит. 2007; 3-е изд. 199 -210.
8. Chomiak T., Turner N., Hu B. What we have learned about autism spectrum disorder from valproic acid. Pathology Research International 2013; 2013: 712-758.
9. Kerr D.M., Downey L., Conboy M., et al. Alterations in the endocannabinoid system in the rat valproic acid model of autism. Behavioural Brain Research 2013; 249: 124-132.
10. Gottfried C., Bambini-Junior V., Baronio D., et al. Valproic Acid in Autism Spectrum Disorder: From an Environmental Risk Factor to a Reliable Animal Model. In: Recent Advances in Autism Spectrum Disorders. InTech, Chapters published. 2013; 1. Ch.8.: 143-163.
11. Silverman J.L., Yang M., Lord K., Crawley J.N. Behavioral phenotyping assay for mouse models of autism. Nat Rev Neurosci. 2010; 11 (7): 490 -502.
12. Foley A.G., Gannon S., Rombach-mullan N., et al. Class I histone deacetylase inhibition ameliorates social cognition and cell adhesion molecule plasticity deficits in a rodent model of autism spectrum disorder. Neuropharmacology 2012;63(4): 750-760.
13. Ingram J.L., Peckham S.M., Tisdale B., Rodier P.M. Prenatal exposure of rats to valproic acid reproduces the cerebellar anomalies associated with autism. Neurotoxicology and Teratology 2000; 22: 319-324.
14. Crawley J.N. Designing mouse behavioral tasks relevant to autistic-like behaviors. Mental Retardation and Developmental Disabilities Research Reviews 2004; 10: 248-58.
15. Kaidanovich-Beilin O., Lipina T., Vukobradovic I., Roder J., Woodgett J.R. Assessment of Social Interaction Behaviors. J. Vis. Exp. 2011; 48: 2473.
16. Островская Р.У., Раевский К.С., Воронина Т.А. и др. в «Руководстве по проведению доклинических исследований лекарственных средств» Часть 1, Москва, изд-во «Гриф и К» ФГБУ «НЦЭМСП» Минздравсоцразвития России, 2012; 251-263.
17. Калинина Т.С., Шимширт А.А., Кудряшов Н.В. и др. Нейростеро-идогенез и ориентировочно-исследовательское поведение грызунов. Экспер. и клин. фармак. 2014; 77 (2): 3-7.
18. Yusuf S, Adelaiye A, Agunu A. Effect of Ziziphus mauritiania (L.) seed extracts on spatial recognition memory of rats as measured by the Y-maze test. Journal of Natural Products. 2009; 2: 31-39.
19. Iwata K., Izumo N., Matsuzaki H., et al. Vldlr overexpression causes hyperactivity in rats. Molecular Autism 2012; 3: 11.
Review
For citations:
Kapitsa I.G., Ivanova E.A., Voronina T.A., Protsun G.V. Effect of triftazin (trifluoperazine) on the symptoms of autism spectrum disorders in rats with fetal valproatate syndrome. Pharmacokinetics and Pharmacodynamics. 2017;(3):34-38. (In Russ.)
Views:
745
Email this article 